Breast Cancer

A breast cancer survivorship expert shares her top advice for counseling patients on endocrine therapy at the 5-year mark.

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, explains how educating patients about the Breast Cancer Index can support informed endocrine therapy decisions.

Treatment decisions for older adults after CDK4/6 inhibitors should be tailored, explained Courtney Moore, APRN, FNP-C, OCN.

For patients with HR-positive breast cancer, adverse effects vary by CDK4/6 inhibitor, says Courtney Moore, APRN, FNP-C, OCN.

Kimberly Podsada, BSN, RN, MSN, NP-C, CNS, explained that understanding a patient’s emotional needs can help educate them on treatment adherence.

Hope S. Rugo, MD, FASCO, outlined the top considerations for nurses managing toxicities related to PI3K and AKT inhibitors in patients with breast cancer.

Survivorship expert Michelle Kirschner, MSN, RN, ACNP, APRN-BC, says that “doable changes” can enhance the lives of patients surviving cancer.

Adding aprepitant to chemotherapy was linked to longer survival in patients with non-luminal breast cancers, especially triple-negative breast cancer.

Hope S. Rugo, MD, FASCO, emphasized the importance of educating patients about proactive rash and diarrhea management while taking PI3K/AKT inhibitors.

Pooled data from early-phase trials suggest JSKN003 is tolerable and active in patients with heavily pretreated HER2-positive disease.

Establishing a routine early in treatment helps proactively manage adverse effects associated with CDK4/6 inhibitors, says Kimberly Podsada, BSN, RN, MSN, NP-C, CNS.

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2- mBC.

Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.

Those who took olanzapine reported higher levels of satisfaction than patients on placebo.

KN026 plus KN046 produced sustained responses and showed a manageable safety profile in pretreated patients with HER2-positive advanced breast cancer.

Gedatolisib-based combinations yielded encouraging responses in patients with mCRPC and HER2-positive metastatic breast cancer, early trial data show.

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Because oncology nurses are at the forefront of patient care, they are uniquely positioned to facilitate cancer survivorship and lymphedema prevention.

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

Treatment with imlunestrant was especially impactful to quality of life and global health status for patients with ESR1 mutations.

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

Camizestrant plus CDK4/6 inhibition improved PFS vs standard care in patients with ER+/HER2– advanced breast cancer and emergent ESR1 mutations.

Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.

Panelists discuss the EMERALD trial data, which shows the effectiveness of elacestrant in patients with estrogen receptor 1 (ESR1) mutations, particularly those who were on first-line CDK 4/6 inhibitors for longer than a year.